Peptide Initiative

Peptides · Peptide comparison

Dulaglutide vs Liraglutide

Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required

FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeDulaglutide1.5–1.5 mgLiraglutide1.2–1.8 mg
FrequencyDulaglutideOnce weeklyLiraglutideOnce daily
AdministrationDulaglutideSubcutaneous injectionLiraglutideSubcutaneous injection
Cycle lengthDulaglutideOngoing/indefiniteLiraglutideOngoing/indefinite
Onset speedDulaglutideGradual (3-4 weeks)LiraglutideGradual (3-4 weeks)
Evidence levelDulaglutideStrong human trials (Phase 3 or FDA approved)LiraglutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Metabolic

Dulaglutide9%
Liraglutide9%

Weight Management

Dulaglutide8%
Liraglutide9%

Healing & Recovery

Dulaglutide8%
Liraglutide8%

Technical data

Compound specifications

Dulaglutide

Molecular formula
C2646H4044N704O836S18 (complete fusion protein homodimer)
Molecular weight
~63 kDa (~59,670 Da per chain)
Half-life
~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg
Bioavailability
47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h
CAS number
923950-08-7

Liraglutide

Molecular formula
C172H265N43O51
Molecular weight
3,751 Da
Half-life
~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days
Bioavailability
~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety
CAS number
204656-20-2

Protocols

Dosing compared

Dulaglutide

Subcutaneous

  • 4 weeks before increasing0.75 mgOnce weekly · 4 weeks before increasingFDA-approved starting dose for type 2 diabetes. Injected under the skin of the abdomen, thigh, or upper arm on the same day each week [4].
  • Ongoing1.5 mgOnce weekly · OngoingCommon maintenance dose. The dose can be raised from 0.75 mg after at least 4 weeks if more blood-sugar control is needed [1][4].
  • Ongoing3.0–4.5 mgOnce weekly · OngoingFDA-approved higher doses. In the AWARD-11 trial, stepping up to 3.0 mg then 4.5 mg gave added blood-sugar and weight benefits; 4.5 mg is the maximum dose [1].

Liraglutide

Subcutaneous

  • Week 10.6 mgOnce daily · Week 1FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation [6].
  • Ongoing1.2-1.8 mgOnce daily · OngoingVictoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control is needed [6].
  • Ongoing3.0 mgOnce daily · OngoingSaxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) [6].

Applications

Best suited for

Dulaglutide

Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Liraglutide

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].

Safety profile

Side effects

Dulaglutide

Common

  • Nausea
  • Diarrhea and abdominal pain
  • Vomiting
  • Decreased appetite

Uncommon

  • Injection site reactions and fatigue

Serious

  • Acute pancreatitis
  • Gallbladder disease

Liraglutide

Common

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite and headache

Uncommon

  • Injection site reactions

Serious

  • Acute pancreatitis
  • Gallbladder disease

Research status

Safety & evidence

Dulaglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC [6] or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
  • Known serious hypersensitivity to dulaglutide or any excipient [6]
  • Type 1 diabetes mellitus or diabetic ketoacidosis (not indicated) [6]

Liraglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation [6] but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
  • Known hypersensitivity to liraglutide or any excipients [6]

Decision guide

Which is right for you?

Dulaglutide

Choose Dulaglutide if…

  • Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
  • Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
  • Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
  • Pediatric patients aged 10–17 with type 2 diabetes (approved indication)

Liraglutide

Choose Liraglutide if…

  • Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
  • Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
  • Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
  • Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile